REGULATED PRESS RELEASE published on 05/23/2025 at 07:30, 10 months 3 days ago Vif succès de l’augmentation de capital de NFL Biosciences avec une levée plafonnée à 3 millions d’euros NFL Biosciences annonce une levée de fonds réussie de 3 millions d'euros pour financer son candidat médicament contre l'addiction au tabac. Allocation des fonds pour une étude de Phase 3 de NFL-101 NFL Biosciences NFL-101 Levée De Fonds Phase 3 Addiction Au Tabac
BRIEF published on 05/22/2025 at 17:50, 10 months 3 days ago NFL Biosciences Announces €2.2 Million Capital Increase NFL Biosciences Clinical Trials Capital Increase Biopharmaceuticals Investment Risks
BRIEF published on 05/22/2025 at 17:50, 10 months 3 days ago NFL Biosciences annonce une levée de fonds de 2,2 millions d'euros Augmentation De Capital NFL-101 Levée De Fonds Phase 3 Plateforme PrimaryBid
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 10 months 3 days ago NFL Biosciences lance une levée de fonds d’environ 2,2 millions d’euros par voie d’augmentations de capital NFL Biosciences lance une levée de fonds de 2,2 millions d'euros pour étude sur le traitement des addictions avec nouveau médicament NFL-101 NFL Biosciences NFL-101 Levée De Fonds Addictions Étude Phase 3
REGULATED PRESS RELEASE published on 05/22/2025 at 17:45, 10 months 3 days ago NFL Biosciences launches a capital increase of approximately €2.2 million NFL Biosciences launches a €2.2 million capital increase through global offering for smoking cessation drug development. Subscription price: €1.20/share NFL Biosciences Capital Increase Smoking Cessation Subscription Price Global Offering
BRIEF published on 05/21/2025 at 17:50, 10 months 4 days ago Résultats de l'Assemblée Générale de NFL Biosciences NFL Biosciences Actionnaires Assemblée Générale Biopharmaceutique Resolutions
BRIEF published on 05/21/2025 at 17:50, 10 months 4 days ago NFL Biosciences General Meeting Results NFL Biosciences Shareholders Biopharmaceuticals Resolutions General Assembly
REGULATED PRESS RELEASE published on 05/21/2025 at 17:45, 10 months 4 days ago NFL Biosciences : compte rendu de l’assemblée générale mixte du 21 mai 2025 Compte rendu de l'assemblée générale mixte de NFL Biosciences du 21 mai 2025. Résolutions approuvées pour le développement de médicaments botaniques innovants pour traiter les addictions NFL Biosciences Médicaments Botaniques Assemblée Générale Mixte Résolutions Approuvées Addictions
BRIEF published on 05/12/2025 at 08:35, 10 months 13 days ago NFL Biosciences Restructures Scientific Committee for NFL-101 Advancement NFL Biosciences NFL-101 Phase 3 Trials Tobacco Addiction Scientific Committee
BRIEF published on 05/12/2025 at 08:35, 10 months 13 days ago NFL Biosciences renforce son Comité Scientifique pour le développement de NFL-101 NFL Biosciences NFL-101 Phase 3 Addiction Tabac Comité Scientifique
Published on 03/26/2026 at 04:55, 3 hours 11 minutes ago Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives
Published on 03/26/2026 at 00:40, 7 hours 26 minutes ago Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 7 hours 36 minutes ago Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 12 hours 51 minutes ago Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 18 hours 36 minutes ago Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/26/2026 at 07:45, 21 minutes ago Eckert & Ziegler: Strong FY 2025 with Positive Outlook
Published on 03/26/2026 at 07:36, 30 minutes ago Medios achieves double-digit revenue growth and improves profitability
Published on 03/26/2026 at 07:30, 36 minutes ago Bike24 Holding AG: Accelerated growth in 2025 fueled by greater market reach, stronger results and enhanced financial stability
Published on 03/26/2026 at 07:30, 36 minutes ago SFC Energy AG publishes annual report for 2025 – return to growth in Q4 with high profitability – wider share of defense and security applications boosting outlook for further growth in 2026
Published on 03/26/2026 at 07:30, 36 minutes ago Scout24 SE publishes integrated annual report 2025 and proposes 14% dividend increase; guidance for 2026 reiterated
Published on 03/26/2026 at 07:30, 36 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/26/2026 at 07:30, 36 minutes ago BIOPHYTIS ET LYNXKITE INVITÉS À LA CONFÉRENCE NVIDIA : L’IA AU SERVICE DE LA LONGÉVITÉ
Published on 03/25/2026 at 18:53, 13 hours 12 minutes ago CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026
Published on 03/25/2026 at 18:31, 13 hours 35 minutes ago Strong investment performance and active roll-out of our strategy
